ID   NS0
AC   CVCL_3940
SY   NSO; NS/0; NS/O
DR   BTO; BTO:0004968
DR   CLO; CLO_0008203
DR   CLO; CLO_0008206
DR   CLO; CLO_0050179
DR   CLDB; cl3737
DR   CLDB; cl3738
DR   CLDB; cl3739
DR   ChEMBL-Cells; CHEMBL3307752
DR   ChEMBL-Targets; CHEMBL615003
DR   ECACC; 85110503
DR   FCS-free; 110-17-508-1-16-3
DR   IZSLER; BS TCL 48
DR   Lonza; 757
DR   NCBI_Iran; C142
DR   PubChem_Cell_line; CVCL_3940
DR   RCB; RCB0213
DR   TKG; TKG 0594
DR   Wikidata; Q20164415
RX   PubMed=18617141;
RX   PubMed=19003032;
WW   https://en.wikipedia.org/wiki/NS0_cell
CC   Group: Hybridoma fusion partner cell line.
CC   Characteristics: Commonly employed for monoclonal antibody expression.
CC   Characteristics: Lacks endogenous glutamine synthetase (GS) activity.
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC   Breed/subspecies: BALB/c.
DI   NCIt; C125417; Mouse plasma cell myeloma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2155 ! P3/NS1/1-Ag4.1
SX   Female
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 16
//
RX   PubMed=18617141; DOI=10.1016/j.jprot.2008.02.003;
RA   de la Luz-Hernandez K.R., Rojas-del Calvo L., Rabasa-Legon Y.,
RA   Lage-Castellanos A., Castillo-Vitlloch A., Diaz J., Gaskell S.;
RT   "Metabolic and proteomic study of NS0 myeloma cell line following the
RT   adaptation to protein-free medium.";
RL   J. Proteomics 71:133-147(2008).
//
RX   PubMed=19003032; DOI=10.1007/s10616-005-3563-z;
RA   Zhang J.-Y., Robinson D.;
RT   "Development of animal-free, protein-free and chemically-defined media
RT   for NS0 cell culture.";
RL   Cytotechnology 48:59-74(2005).
//